HeartVista is a technology company.
HeartVista has raised $9.0M across 1 funding round.
HeartVista has raised $9.0M in total across 1 funding round.
HeartVista has raised $9.0M in total across 1 funding round.
HeartVista's investors include Cervin Ventures, Dell Technologies Capital, Hanabi Capital, Khosla Ventures, Morgenthaler Ventures, Redpoint Ventures, TriplePoint Capital.
HeartVista (now Vista AI) is a technology company that develops AI-powered software to automate and simplify MRI acquisition, initially focusing on cardiac MRI (CMR) but expanding to other anatomical areas. Their flagship product, Vista AI Scan, enables real-time, one-click MRI scanning that improves efficiency, accessibility, and diagnostic accuracy for hospitals and research institutions. The software serves clinicians, radiologists, and imaging centers by addressing the complexity, time, and staffing challenges of MRI exams, particularly cardiac imaging, which is considered the gold standard for diagnosing heart disease[1][2][4][6].
Founded by Juan Santos, William Overall, and Bob Hu—researchers from Stanford's Magnetic Resonance Systems Research Lab—HeartVista emerged from the recognition that AI could automate MRI scanning to improve patient care and access. Early NIH Small Business Innovation Research grants supported their development, leading to FDA clearance in 2019 for their AI-assisted cardiac MRI software. The company has since grown, secured venture funding (notably from Khosla Ventures), and licensed its technology to over twenty universities worldwide. In 2022, HeartVista rebranded as Vista AI to reflect its broader mission of automating MRI scans beyond the heart to other anatomies like the prostate and musculoskeletal system[2][3][4].
Vista AI rides the growing trend of applying artificial intelligence to medical imaging to improve diagnostic workflows and patient outcomes. The timing is critical due to increasing demand for MRI scans, staffing shortages, and the complexity of imaging protocols. By automating MRI acquisition, Vista AI addresses these market pressures, enabling healthcare providers to deliver gold-standard imaging more efficiently and broadly. This innovation supports the shift toward precision medicine and value-based care by improving scan consistency, reducing costs, and expanding access to advanced diagnostics[2][6].
Vista AI is poised to expand its influence by broadening its AI automation platform beyond cardiac MRI to other organ systems, potentially transforming MRI accessibility and efficiency across healthcare. Future trends shaping their journey include continued AI integration in medical imaging, regulatory acceptance of autonomous diagnostic tools, and growing healthcare demand for scalable, cost-effective imaging solutions. As Vista AI scales, it may become a key enabler of standardized, high-quality MRI diagnostics worldwide, fulfilling its vision of making gold-standard MRI universally available[2][6].
In summary, HeartVista (Vista AI) exemplifies how AI-driven automation can revolutionize complex medical imaging workflows, improving patient care and operational efficiency in a critical healthcare domain.
HeartVista has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Series A in April 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2020 | $9.0M Series A | Cervin Ventures, Dell Technologies Capital, Hanabi Capital, Khosla Ventures, Morgenthaler Ventures, Redpoint Ventures, TriplePoint Capital |